Phase 1b/2 – A Randomised, Single-Blind, Placebo Controlled, Multiple Dose, Dose Escalation Study to Evaluate the Safety and Tolerability of EXN407 in subjects with Centre Involved Diabetic Macular Oedema secondary to Diabetes Mellitus.
ClinicalTrials.gov identifier: NCT04565756
Principal Investigator – Dr Fred Chen
For more information please contact the Clinical Trials Office on (08) 9381 0750 or email clinicalresearch@lei.org.au